Authors
Andrea Varga, Éva Gráczer, Laurent Chaloin, Károly Liliom, Péter Závodszky, Corinne Lionne, Mária Vas
Publication date
2013/1/23
Journal
European Journal of Pharmaceutical Sciences
Volume
48
Issue
1-2
Pages
307-315
Publisher
Elsevier
Description
Nucleoside analogues, used in HIV-therapy, need to be phosphorylated by cellular enzymes in order to become potential substrates for HIV reverse transcriptase. After incorporation into the viral DNA chain, because of lacking of their 3′-hydroxyl groups, they stop the elongation process and lead to the death of the virus. Phosphorylation of the HIV-drug derivative, tenofovir monophosphate was tested with the recombinant mammalian nucleoside diphosphate kinase (NDPK), 3-phosphoglycerate kinase (PGK), creatine kinase (CK) and pyruvate kinase (PK). Among them, only CK was found to phosphorylate tenofovir monophosphate with a reasonable rate (about 45-fold lower than with its natural substrate, ADP), while PK exhibits even lower, but still detectable activity (about 1000-fold lower compared to the value with ADP). On the other hand, neither NDPK nor PGK has any detectable activity on tenofovir …
Total citations
201420152016201720182019202020212022202320242361341211
Scholar articles
A Varga, É Gráczer, L Chaloin, K Liliom, P Závodszky… - European Journal of Pharmaceutical Sciences, 2013